David Hochman Net Worth

The estimated Net Worth of David P Hochman is at least $179 Mille dollars as of 4 December 2020. Mr. Hochman owns over 5,000 units of Motus GI Inc stock worth over $2,368 and over the last 10 years he sold MOTS stock worth over $0. In addition, he makes $176,920 as Independent Chairman of the Board at Motus GI Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hochman MOTS stock SEC Form 4 insiders trading

David has made over 20 trades of the Motus GI Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of MOTS stock worth $4,950 on 4 December 2020.

The largest trade he's ever made was buying 115,000 units of Motus GI Inc stock on 16 February 2018 worth over $575,000. On average, David trades about 7,313 units every 58 days since 2014. As of 4 December 2020 he still owns at least 76,373 units of Motus GI Inc stock.

You can see the complete history of Mr. Hochman stock trades at the bottom of the page.

David Hochman biography

David P. Hochman serves as Independent Chairman of the Board of the Company. Mr. Hochman has served as our Chairman of the Board since 2016, and as Chairman of the Board of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, since 2011. Since May 2018, he has been Chairman and Chief Executive Officer of Orchestra BioMed, Inc., a biomedical innovation company focused on developing high impact therapeutic solutions to address significant unmet needs. Since 2006, he has been Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employs a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value. Mr. Hochman has also served as President of Accelerated Technologies, Inc., a medical device accelerator company managed by Orchestra Medical Ventures, LLC. Mr. Hochman has over twenty-one years of healthcare entrepreneurial, venture capital and investment banking experience. Mr. Hochman currently serves as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. He was a co-founder of Caliber Therapeutics, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and was on the Board of Caliber Therapeutics, Inc. from 2009 until 2018. He was a co-founder of BackBeat Medical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as its President and a member of its Board since inception in 2010 until 2018. He was a co-founder of FreeHold Surgical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as a member of its Board from 2011 until 2018. He also serves as a director of Adgero Biopharmaceuticals Holdings, Inc. He has a B.A. degree with honors from the University of Michigan.

What is the salary of David Hochman?

As the Independent Chairman of the Board of Motus GI Inc, the total compensation of David Hochman at Motus GI Inc is $176,920. There are 6 executives at Motus GI Inc getting paid more, with Timothy Moran having the highest compensation of $1,659,360.

How old is David Hochman?

David Hochman is 44, he's been the Independent Chairman of the Board of Motus GI Inc since 2016. There are 10 older and no younger executives at Motus GI Inc. The oldest executive at Motus GI Holdings Inc is Samuel Nussbaum, 71, who is the Independent Director.

What's David Hochman's mailing address?

David's mailing address filed with the SEC is C/O MOTUS GI HOLDINGS, INC., 1301, EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE,, FL, 33301.

Insiders trading at Motus GI Inc

Over the last 7 years, insiders at Motus GI Inc have traded over $2,638,819 worth of Motus GI Inc stock and bought 3,952,265 units worth $13,986,863 . The most active insiders traders include Advisors Llcperceptive Life..., Larry Noracle Partners Lp F... e David P Hochman. On average, Motus GI Inc executives and independent directors trade stock every 33 days with the average trade being worth of $4,105. The most recent stock trade was executed by Andrew Lawrence Taylor on 19 November 2021, trading 2,000 units of MOTS stock currently worth $1,020.

What does Motus GI Inc do?

motus gi holdings, inc. (nasdaq: mots) is a medical technology company based in the u.s., with subsidiaries in the u.s. and israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. the company is focused on the development and commercialization of the pure-vu® system, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. the pure-vu® system is a 510(k) u.s. food and drug administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. the device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. the pure-vu® system has received ce mark approval in europe.

Complete history of Mr. Hochman stock trades at Corbus Pharmaceuticals Inc e Motus GI Inc

Motus GI Inc executives and stock owners

Motus GI Inc executives and other stock owners filed with the SEC include:

• Timothy Moran,
  Chief Executive Officer, Director
• Timothy P. Moran,
  CEO & Director
• Mark Pomeranz,
  President, Chief Operating Officer, Director
• Andrew Taylor,
  Chief Financial Officer
• Mark Pomeranz,
  Pres, COO & Director
• Andrew Lawrence Taylor M.B.A.,
  Chief Financial Officer
• David Hochman,
  Independent Chairman of the Board
• Bob Yedid,
  Managing Director
• Darren Sherman,
  Independent Director
• Gary Pruden,
  Independent Director
• Samuel Nussbaum,
  Independent Director
• Shervin Korangy,
  Independent Director
• Scott C. Aldrich Jr.,
  VP of Marketing & Strategy
• Llc Abv,,
  
• Gary E. Jacobs,
  Director
• Biomedical Ventures Ii, L.P...,
  
• Advisors Llcperceptive Life...,
  
• Larry Noracle Partners Lp F...,
  
• Scott Durbin,
  Director
• Sonja Nelson,
  Director